Chennai-based Iswarya Fertility Center secured over ₹350 crore (approximately $37 million) in growth funding from healthcare investment firm OrbiMed Asia, the company announced on Thursday. The investment aims to support Iswarya's expansion in India's fertility care market, which is experiencing increased investor interest amid changing demographic trends.
The funding round will enable Iswarya Fertility Center to open new centers in both existing and underserved regions across India. The company plans to enhance its clinical infrastructure, boost digital capabilities, and expand its embryology talent pool. Dr. Arun Muthuvel, managing director at Iswarya Fertility Center, emphasized the focus on deepening pan-India presence and improving clinical outcomes.
This investment by OrbiMed Asia marks an extension of the US-headquartered firm's portfolio into the fertility care sector in India. The fertility care market in India has been attracting growing attention due to shifting demographics and rising demand for specialized reproductive health services. Comparable deals in the healthcare sector reflect a broader trend of increased funding in niche medical services.
Iswarya Fertility Center's announcement on July 9 highlights a strategic push to enter underserved geographies and strengthen its service offerings. The company’s next steps include establishing new centers and enhancing its clinical and digital infrastructure to meet growing demand in the fertility care space.